Tennessee Lawmaker Pushes Medical Cannabis Session Amid Federal Shift

A Tennessee state representative is pushing for a special legislative session dedicated to medical marijuana policy as federal cannabis rescheduling discussions gain traction under the Trump administration. The move represents a strategic attempt to align state-level cannabis policy with anticipated federal regulatory changes that could reshape the industry landscape.

Tennessee remains one of the most restrictive states for cannabis access, with only limited CBD oil permitted for specific medical conditions. The call for a special session signals growing political pressure within traditionally conservative states to establish medical cannabis frameworks before federal rescheduling potentially creates regulatory gaps or competitive disadvantages.

Federal rescheduling from Schedule I to Schedule III would eliminate the 280E tax burden that currently crushes cannabis operators' margins, potentially boosting profitability across major multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF). States without established medical programs risk losing out on tax revenue and regulated market development as federal barriers diminish.

The Tennessee initiative reflects broader momentum building across conservative states as federal policy shifts create urgency around cannabis legislation. Similar discussions are emerging in states like South Carolina and Kansas, where lawmakers recognize that federal rescheduling could accelerate interstate commerce and leave restrictive states at economic disadvantages.

For cannabis investors, state-level policy developments in previously restrictive markets represent significant expansion opportunities. Multi-state operators with capital and operational expertise stand to benefit most from rapid market openings, particularly in southeastern states where limited competition could drive higher margins than mature markets like California and Colorado.